Karista

Founded in 2020, Beev is a Paris-based company offering electric vehicle solutions. It facilitates the acquisition of electric vehicles along with charging station installation for residential, business, and public spaces.

Founded in 2017, UpFactor specializes in site analysis services using GIS technology. It aggregates data such as addresses, street widths, building heights, land use plans, solar potential registers, and protected areas to assess building potentials.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Admo.tv is the best TV analytics platform that helps TV & radio advertisers to measure and optimise the online impact of their offline investments. Admo.tv optimises, in average, about 30% the R.O.I. of its clients by providing the finest analysis in terms of incremental visits and conversion of their media investments. Admo.tv is a start-up that has offices in Paris and operates in more than 12 different countries worldwide. Admo.tv optimise every day the offline investments of the best advertising agencies (Dentsu Aegis, Havas…) and top-tier brands such as Accor, Allianz, Ford, Meetic, La Redoute, and more.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

AppScho, SAS, established in 2014 and headquartered in Paris, France, specializes in mobile application software for higher education. Its application centralizes essential information for students and educational institutions, providing access to schedules, grades, school events, and employment opportunities. The app enhances student engagement by offering features such as course previews, classroom details, and notifications for schedule changes. Additionally, it facilitates communication between institutions and students, allowing educators to monitor student engagement and analyze performance. By streamlining campus content and services, AppScho aims to improve the overall academic experience and support students in managing their studies effectively.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

BnbSitter, established in 2013 and headquartered in Paris, France, specializes in streamlining short-term rental management. Through its online platform, the company offers on-demand concierge services, enabling vacation rental hosts to book essential services like guest check-in/check-out and rental cleaning swiftly and efficiently, ensuring a smooth and welcoming experience for guests.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

Melusyn offers an interactive platform that enables film product crews to keep track of and optimize their schedules. It enables teams to communicate with each other; keep track of decorations, casting, and costumes; keep track of time; and more. Melusyn is based in Paris, France.

Melusyn offers an interactive platform that enables film product crews to keep track of and optimize their schedules. It enables teams to communicate with each other; keep track of decorations, casting, and costumes; keep track of time; and more. Melusyn is based in Paris, France.

TISSIUM is a Paris-based medical device company focused on biodegradable programmable polymer technology for tissue reconstruction and surgical wound closure, particularly in minimally invasive procedures. Its non-toxic sealants and adhesives are designed to bind strongly to tissues and provide immediate closure in the body's wet, dynamic environments, enabling rapid wound management across multiple clinical areas. The company builds on intellectual property and research associated with leading researchers Robert Langer and Jeff Karp. These core capabilities support applications in tissue repair and potential localized drug delivery.

e(ye)BRAIN SA is a medical company specializing in the development and manufacturing of eye trackers designed for the diagnosis of neurological and psychiatric diseases. Founded in 2008 and based in Paris, France, the company offers two primary products: EyeBrain T1 and EyeBrain T2. The EyeBrain T1 allows users to record eye movements, while the EyeBrain T2 incorporates advanced algorithms to capture both eye and head movements. These recorded movements are then analyzed using the MeyeEval software. In addition to its product offerings, e(ye)BRAIN provides advisory, paradigm development, training, and support services to its clients, enhancing their capabilities in clinical research and functional exploration of both healthy and diseased brains.

e(ye)BRAIN SA is a medical company specializing in the development and manufacturing of eye trackers designed for the diagnosis of neurological and psychiatric diseases. Founded in 2008 and based in Paris, France, the company offers two primary products: EyeBrain T1 and EyeBrain T2. The EyeBrain T1 allows users to record eye movements, while the EyeBrain T2 incorporates advanced algorithms to capture both eye and head movements. These recorded movements are then analyzed using the MeyeEval software. In addition to its product offerings, e(ye)BRAIN provides advisory, paradigm development, training, and support services to its clients, enhancing their capabilities in clinical research and functional exploration of both healthy and diseased brains.

Sequans Communications designs and supplies cellular semiconductor solutions for broadband Internet of Things markets, offering 5G and 4G chips and modules for massive, broadband, and critical IoT applications. Its product platforms include Monarch LTE-M/NB-IoT and Calliope Cat 1 for low-power, integrated IoT deployments, Cassiopeia Cat 4/Cat 6 for 4G and 5G, and Taurus for residential, enterprise, and industrial use. Founded in 2003 and headquartered in Paris, the company operates globally with offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China. Its customer base spans smart mobility and logistics, smart utility meters, smart cities and industries, e-health, and smart homes, reflecting a focus on cellular semiconductor solutions for a range of IoT connectivity needs.

Sequans Communications designs and supplies cellular semiconductor solutions for broadband Internet of Things markets, offering 5G and 4G chips and modules for massive, broadband, and critical IoT applications. Its product platforms include Monarch LTE-M/NB-IoT and Calliope Cat 1 for low-power, integrated IoT deployments, Cassiopeia Cat 4/Cat 6 for 4G and 5G, and Taurus for residential, enterprise, and industrial use. Founded in 2003 and headquartered in Paris, the company operates globally with offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China. Its customer base spans smart mobility and logistics, smart utility meters, smart cities and industries, e-health, and smart homes, reflecting a focus on cellular semiconductor solutions for a range of IoT connectivity needs.

Sequans Communications designs and supplies cellular semiconductor solutions for broadband Internet of Things markets, offering 5G and 4G chips and modules for massive, broadband, and critical IoT applications. Its product platforms include Monarch LTE-M/NB-IoT and Calliope Cat 1 for low-power, integrated IoT deployments, Cassiopeia Cat 4/Cat 6 for 4G and 5G, and Taurus for residential, enterprise, and industrial use. Founded in 2003 and headquartered in Paris, the company operates globally with offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China. Its customer base spans smart mobility and logistics, smart utility meters, smart cities and industries, e-health, and smart homes, reflecting a focus on cellular semiconductor solutions for a range of IoT connectivity needs.